Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines

BJU International

Volumn 90, Issue 1, 2002, Pages 113-117

  Hong, J H ^a   Lee, E ^b   Hong, J ^a   Shin, Y J ^a   Ahn, H ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Antisense oligonucleotide; Bcl2; Bladder cancer; Chemoresistance

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; PROTEIN BCL 2;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLETHANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 0036068291     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02799.x     Document Type: Article

References (22)

1. Advanced bladder cancer: The need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) world
2. Overexpression of metallothionein confers resistance to anticancer drugs
3. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
4. cis-Diamminedichloro platinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells
5. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells
6. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
7. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorform extraction
8. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
9. Management of disseminated disease in the patient with bladder cancer
10. Preclinical and clinical experience with cisplatin resistance
11. Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma
12. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
13. Programmed cell death and radioresistance
14. Changes in levels of expression of p53 and the product of the Bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis
15. Bcl-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance
16. Small cell carcinomas of the lung express the Bcl-2 protein
17. Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32
18. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2
19. Therapeutic applications of oligonucleotides
20. Methods of gene delivery
21. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
22. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma